This was the stock's third consecutive day of losses.

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 2.35% to $6.10 Tuesday, on what proved to be an all-around positive ...

Corbus Pharmaceuticals (CRBP) announced the dosing of the first subject in the single ascending dose / multiple ascending dose portion of the ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity ...

Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Wednesday, March ...

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the ...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, trading at $7.87, with InvestingPro data showing the stock is currently trading below its Fair... In a recent ...

Corbus Pharmaceuticals (NASDAQ:CRBP): Q3 GAAP EPS of -$0.26 misses by $0.06. Revenue of $1.09M (+36.3% Y/Y) misses by... BySeeking Alpha • Nov 08, 2018 Corbus Pharma's lenabasum shows positive ...

Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus Pharmaceuticals in a research note issued on Tuesday, March 11th. Lifesci Capital analyst ...